Vectura presents VR040 positive result in Parkinson's trial

PBR, Published 16 November 2010
http://drugdelivery.pharmaceutical-b...s-trial_161110

The results of the study demonstrate that VR040 improves the control of movement in patients with Parkinson's disease and VR040 produced clinically relevant and improvement, compared with placebo, of the Unified Parkinson's Disease Rating Scale Part III (UPDRS III), a measure of a patient's ability to control movement (see Notes for editors).

VR040 also reduced the time patients were in an 'off' state by over 2 hours, a change considered by the investigators to be highly clinically relevant, although not statistically significant, when compared with placebo in the relatively small number of patients tested.